[HTML][HTML] METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing, W Guo… - Molecular cancer, 2022 - Springer
Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer.
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - Molecular …, 2022 - search.ebscohost.com
Background: Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - Molecular …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer.
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - Molecular …, 2022 - europepmc.org
Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
[HTML][HTML] METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - Molecular …, 2022 - ncbi.nlm.nih.gov
Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
[HTML][HTML] METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
W Wan, X Ao, Q Chen, Y Yu, L Ao… - Molecular …, 2022 - molecular-cancer.biomedcentral …
Continual expression of PD-L1 in tumor cells is critical for tumor immune escape and host T
cell exhaustion, however, knowledge on its clinical benefits through inhibition is limited in …
cell exhaustion, however, knowledge on its clinical benefits through inhibition is limited in …
[PDF][PDF] METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N 6-methyladenosine modification of PD-L1 mRNA in breast cancer
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - 2022 - molecular-cancer.biomedcentral …
Background: Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer.
W Wan, X Ao, Q Chen, Y Yu, L Ao, W Xing… - Molecular …, 2022 - europepmc.org
Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …